Innate Pharma S.A. Sponsored ADR
IPHA Healthcare Biotechnology
Innate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.
Follow IPHA
Innate Pharma S.A. Sponsored ADR (IPHA) EV/Sales
As of 16 October 2026, Innate Pharma S.A. Sponsored ADR (IPHA) trades at a EV/Sales of 0.1×. Over the past ten years it has ranged from −1.3× (December 2021) to 0.1× (October 2026) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.1× | — |
| FY2024 | −0.6× | — |
| FY2023 | −0.6× | — |
| FY2022 | −0.9× | — |
| FY2021 | −1.1× | — |
| FY2020 | −1.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 2.1× | (34.45%) |
| Dec 2022 | 3.2× | 121.34% |
| Jun 2022 | 1.4× | (57.34%) |
| Dec 2021 | 3.4× | 141.45% |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| ADAG Adagene Inc. Sponsored ADR compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR | 0.1× |
| WHWK Whitehawk Therapeutics, Inc. compare | 1.9× |
| DTIL Precision BioSciences, Inc. compare | 1.9× |
| CHRS Coherus Oncology, Inc. compare | 5.1× |
| MDWD MediWound Ltd. compare | 10.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 29.0× |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)